Trial Profile
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 21 Oct 2006 New trial record.